WCG acquires pharmacovigilance firm Vigilare

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/oatawa)
(Image: iStock/oatawa)

Related tags: Drug safety, Pharmacology

WIRB Copernicus Group (WCG) has expanded its portfolio of companies to include the pharmacovigilance and drug safety solution provider Vigilare International.

The clinical services organization (CSO) has acquired Conshohocken, PA-based Vigilare International, which provides pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry.

Following the transaction – financial details of which were not disclosed – Vigilare will continue to operate as an independent service organization.

WCG will provide Vigilare access to capital, clinical and regulatory expertise, and corporate support, according to the company.

Craig Sowell, chief marketing officer at WCG told us the company seeks to partner with companies that share "the vision of increasing efficiencies within the clinical trial process.​"

WCG recognized Vigilare as a company with a similar mission and vision, he said.

"The Vigilare approach to providing end-to-end drug safety and pharmacovigilance services to the biopharmaceutical and biotech industry is a natural fit with WCG​," added Sowell.

WCG has made several other acquisitions in 2017, including the global patient recruitment, enrollment, and retention firm, ThreeWire​, as well as MedAvante and ProPhase​. In August, the company also acquired Patient Genesis’ ConsentNow​ electronic consent (eConsent) technology, which joined WCG’s platform of technology-enabled services.

Related news

Show more

Related product

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more